Emily A. Beman

Emily advises biotechnology, pharmaceutical, and other life sciences companies, including AI-focused platform companies, on complex strategic transactions involving the development and commercialization of products and technologies.

Emily has significant experience structuring and negotiating licensing and collaboration agreements, research and development agreements, co-development and commercialization agreements, manufacturing agreements, and other strategic commercial arrangements. She also counsels clients on intellectual property and commercial matters arising in connection with mergers and acquisitions, spinouts, financings, and other corporate transactions.

Emily works with clients at all stages of development, from emerging biotechnology companies pursuing transformative opportunities to established organizations undertaking significant strategic and cross-border initiatives.

A selection of Emily’s representative matters is below:

• ADARx on its collaboration and option agreement with AbbVie to develop small interfering RNA (siRNA) therapeutics across multiple disease areas for $335 million upfront
• Advanced Medical Solutions in its acquisition of Sealantis Limited
• bluebird bio in its strategic collaboration with TC BioPharm
• bluebird bio in its strategic collaboration with Regeneron
• BridgeBio Pharma, Inc., in its joint venture with Maze Therapeutics to advance precision medicine for the treatment of cardiovascular disease
• BridgeBio Pharma, Inc., in its launch of its subsidiary, QED Therapeutics, including its in-license of infigratinib from Novartis
• C4 Therapeutics in its strategic collaboration with Roche to develop degrader-based medicines
• C4 Therapeutics in its strategic collaboration with Calico Life Sciences
• Cephalon in its exclusive license agreement with Eagle Pharmaceuticals, with a total deal value in excess of $120 million plus royalties
• CRISPR Therapeutics in its collaboration with Vertex Pharmaceuticals, valued up to $2.6 billion with $105 million upfront
• CRISPR Therapeutics in its collaboration with ViaCyte, focused on stem cell therapies for the treatment of diabetes
• CRISPR Therapeutics in its novel joint venture with Bayer, valued up to $335 million
• CRISPR Therapeutics in its strategic in-licensing and collaboration agreement with Anagenesis Biotechnologies
• Dren Bio in its sale to Sanofi of its targeted bispecific myeloid cell engager, DR-0201, for $600 million upfront and potential deal value up to $1.9 billion
• Eidos Therapeutics, a BridgeBio company, in connection with a licensing agreement that grants Alexion an exclusive license to develop and commercialize AG10 in Japan
• Eidos Therapeutics, a BridgeBio company, in its $310 million license agreement with Bayer to commercialize acoramidis for transthyretin amyloidosis in Europe
• Enara Bio in its strategic collaboration and license agreement with Boehringer Ingelheim to discover novel shared antigens for cancer immunotherapies
• Enterome in its collaboration with Takeda
• F-star Alpha in its exclusive purchase option agreement with Bristol Myers Squibb for up to $475 million
• Gadeta in its strategic collaboration with Kite (a Gilead company) to develop novel gamma delta TCR therapies for the treatment of various cancers, by way of an option-to-acquire structure
• Kardigan, Inc., in its $460 million initial public offering
• Lacerta in its research, collaboration, and licensing agreement with UCB Biopharma SRL to develop novel gene therapies focused on a central nervous system disease with high unmet need
• Lacerta in its collaboration with Prevail Therapeutics for the discovery and development of novel AAV capsids for CNS diseases
• Naurex in its $560 million sale to Allergan
• Nimbus Therapeutics in its research collaboration and license agreement with Eli Lilly and Company for novel oral obesity treatment for up to $1.3 billion
• Q32 Bio in its collaboration and option agreement with Horizon Therapeutics to research, develop, and commercialize ADX-914 for the treatment of autoimmune diseases for up to $55 million in near-term payments and $645 million in closing and milestone payments
• QED Therapeutics, a BridgeBio company, in its $2.45 billion strategic collaboration with Helsinn
• QED Therapeutics, a BridgeBio company, in its $100 million exclusive license agreement with Kyowa Kirin to develop and commercialize infigratinib for skeletal dysplasias in Japan
• Remedium Bio, Inc., in its multi-target research and development collaboration with Eli Lilly and Company to develop and commercialize gene therapies for obesity and Type 2 diabetes
• Staten Biotechnology in its collaboration with Novo Nordisk to develop novel treatments for dyslipidaemia
• Tessera Therapeutics in its collaboration agreement with Serotiny to engineer and optimize programmable Gene Writer protein
• Teva Pharmaceuticals in its sale of its specialty global women’s health business for a combined value of $2.48 billion, including the sale of the Paragard® business to CooperSurgical for $1.1 billion, the ex-US women’s health business to CVC Capital Partners for $703 million, and the Plan B One-Step® franchise to Foundation Consumer Healthcare for $675 million
• Teva Pharmaceuticals in its $40.5 billion acquisition of Allergan’s global generic pharmaceuticals business
• Teva Pharmaceuticals in connection with its sale of oncology assets to Ignyta
• Teva Pharmaceuticals in connection with patent license and settlement agreements related to various brand and generic pharmaceutical patent litigation matters
• Licensing of intellectual property assets from research institutions

Emily has undertaken a client secondment at bluebird bio.

Prior to joining Goodwin, Emily was a special assistant district attorney in the Kings County District Attorney’s Office.

While in law school, Emily was the Alumni Affairs Editor of the Connecticut Law Review.

Speaker, ACS Mini-Chemical MBA: The Fine Print in Research & IP Agreements, May 2026